Medigen Biotechnology (3176) — Cash Flow Quality Index

Latest as of March 2025: -0.28x

Medigen Biotechnology (3176) has a Cash Flow Quality Index of -0.28x as of March 2025. Operating cash flow of NT$-28.96 Million is below net income of NT$102.45 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Medigen Biotechnology cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

-0.28x

Operating CF / Net Income

Operating Cash Flow

NT$-28.96 Million

TWD

Net Income

NT$102.45 Million

TWD

Data as of

Mar 2025

Most recent filing

Annual Cash Flow Quality Index for Medigen Biotechnology (None–None)

Year-by-year earnings quality comparison for Medigen Biotechnology.

Year	Quality Index	Operating CF (TWD)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.